Original language | English (US) |
---|---|
Pages (from-to) | 23-25 |
Number of pages | 3 |
Journal | European Journal of Cancer |
Volume | 181 |
DOIs | |
State | Published - Mar 2023 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: European Journal of Cancer, Vol. 181, 03.2023, p. 23-25.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Updated analyses for RESTORE cohort C
T2 - A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer
AU - Sena, Laura A.
AU - Wang, Tingchang
AU - Wang, Hao
AU - Markowski, Mark C.
AU - Antonarakis, Emmanuel S.
AU - Denmeade, Samuel R.
N1 - Funding Information: We thank the patients and caregivers who participated in the clinical trial described. This project was supported by the National Institutes of Health , USA ( NIH ) grants P30CA006973 and 1R01CA184012-01. Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ESA is a paid consultant/adviser to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, Lilly, Bayer, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of an AR-V7 biomarker technology that has been licensed to Qiagen. S.R.D. has received research funding to his institution from Astellas. M.C.M. is a paid consultant to Clovis and Exelixis. Other authors declare no conflicts of interest.We thank the patients and caregivers who participated in the clinical trial described. This project was supported by the National Institutes of Health, USA (NIH) grants P30CA006973 and 1R01CA184012-01.
PY - 2023/3
Y1 - 2023/3
UR - http://www.scopus.com/inward/record.url?scp=85146058905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146058905&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2022.12.001
DO - 10.1016/j.ejca.2022.12.001
M3 - Letter
C2 - 36628897
AN - SCOPUS:85146058905
SN - 0959-8049
VL - 181
SP - 23
EP - 25
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -